ReviewJournal of translational medicine2026
Role of mitochondrial dysfunction in muscle wasting in cancer cachexia: a narrative review.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Tuberculosis and Cellular Metabolism: Insights into the Crosstalk Between Macrophage Immunometabolism and Muscle Dysregulation.International journal of molecular sciences · 2026Review
- Sarcopenia and Frailty in COPD: Mechanisms, Relationship with Malnutrition and Potential Therapeutic Interventions.Nutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCancer cachexia is a complex syndrome characterized by significant muscle loss, weight loss, and impaired physical function. One of the core causes of excessive muscle wasting in cancer cachexia patients is mitochondrial dysfunction, which disrupts the energy production and metabolism necessary for muscle function and repair. This review summarizes and synthesizes current evidence on how mitochondrial dysfunction and its associated molecular mechanisms contribute to muscle atrophy in cancer cachexia. MAIN BODY: Mitochondria in muscle cells contribute to maintaining muscle contraction and metabolic activities. Mitochondrial dysfunction, including alterations in mitochondrial biogenesis, mitophagy, and mitochondrial dynamics (fission and fusion), occurs in cancer cachexia. These disturbances result in an insufficient energy supply in muscle cells, leading to excessive muscle wasting. Activation of inflammatory pathways, increased production of reactive oxygen species (ROS), and impairment of mitochondrial protein synthesis pathways are key factors contributing to this dysfunction. Successful restoration of mitochondrial function offers hope for slowing muscle wasting induced by cancer cachexia. We explore various strategies that help restore mitochondrial function to prevent or alleviate muscle wasting. For example, the overexpression of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), AMP-activated protein kinase (AMPK), and silent information regulator 1 (SIRT1), as well as regular exercise, can maintain mitochondrial health and help reduce muscle wasting. In addressing these complex mechanisms, we also discuss the potential of targeting mitochondrial dysfunction as a therapeutic strategy for muscle wasting in cancer cachexia through agents such as small molecule inhibitors of mitochondrial dynamics, antioxidants targeting mitochondrial ROS, natural products such as curcumin, and nutritional supplements such as leucine and creatine.
conclusionsRestoration of mitochondrial function is a promising strategy to combat excessive muscle wasting induced by cancer cachexia. Further research on the precise regulation of mitochondrial dynamics and clinical trials of targeted therapies are crucial for the development of effective methods to treat cancer-associated muscle wasting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.